The KONAR-MF™ occluder safely closed muscular ventricular septal defects in 50 pediatric patients, significantly reducing mean pulmonary artery pressure from 37 to 19 mmHg (p < 0.001).
Does transcatheter and hybrid closure using the KONAR-MF™ occluder improve outcomes and safety in paediatric patients with muscular ventricular septal defects?
The KONAR-MF™ occluder is a safe and effective option for transcatheter closure of muscular ventricular septal defects in paediatric patients, significantly reducing pulmonary artery pressures with minimal complications.
Tasa de eventos absoluta: 0% vs 0%
Abstract Background: The KONAR-MF™ occluder, with its flexible medium-profile design, has broadened the feasibility of transcatheter closure of muscular ventricular septal defects, particularly in infants. Objective: To assess feasibility, safety, techniques, and outcomes of muscular ventricular septal defect closure using the KONAR-MF™ occluder in a multicentre paediatric cohort. Methods: A retrospective review was conducted at three tertiary paediatric cardiac centres (2018–2024). Patient demographics, ventricular septal defect characteristics, procedural approaches, and follow-up outcomes were analysed. Device implantation was performed via retrograde, antegrade, transseptal, or hybrid approaches under fluoroscopic and echocardiographic guidance. Results: Fifty patients (54 devices) were included (median age: 48 months interquartile range 12–96; weight: 12 kg interquartile range 7.5–23), including 14 infants (9 < 7 kg). Indications were failure to thrive (46%), heart failure (28%), recurrent infections (12%), and postoperative residual ventricular septal defect (14%). The mean ventricular septal defect size was 5.8 ± 2 mm. Median fluoroscopy time was 18 minutes (range: 3–71). Residual shunts were present in 18% immediately, reducing to 9% at one week and resolving by three months. Mild, transient tricuspid regurgitation occurred in 14%. Over a median 9-month follow-up (range 1–60), no cases of heart block or haemolysis occurred. One embolisation required surgical retrieval. Pulmonary artery pressure decreased significantly (37 ± 13.4 to 19 ± 3.8 mmHg, p < 0.001). Conclusions: Transcatheter closure of muscular ventricular septal defects with the KONAR-MF™ occluder is safe, effective, and versatile across paediatric age groups, including infants and postoperative cases. High success rates, minimal complications, and favourable short- to mid-term outcomes support its use in routine practice.
Sastry et al. (Tue,) reported a other. The KONAR-MF™ occluder safely closed muscular ventricular septal defects in 50 pediatric patients, significantly reducing mean pulmonary artery pressure from 37 to 19 mmHg (p < 0.001).